CN110520416A - 多取代吡啶酮类衍生物、其制备方法及其医药用途 - Google Patents

多取代吡啶酮类衍生物、其制备方法及其医药用途 Download PDF

Info

Publication number
CN110520416A
CN110520416A CN201880024273.6A CN201880024273A CN110520416A CN 110520416 A CN110520416 A CN 110520416A CN 201880024273 A CN201880024273 A CN 201880024273A CN 110520416 A CN110520416 A CN 110520416A
Authority
CN
China
Prior art keywords
heteroaryl
aryl
alkyl
cycloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880024273.6A
Other languages
English (en)
Other versions
CN110520416B (zh
Inventor
段茂圣
刘佳乐
田世鸿
戴权
熊艳林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Puhe Pharmaceutical Technology Co ltd
Original Assignee
Beijing Yuezhikangtai Biomedicines Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Yuezhikangtai Biomedicines Co ltd filed Critical Beijing Yuezhikangtai Biomedicines Co ltd
Publication of CN110520416A publication Critical patent/CN110520416A/zh
Application granted granted Critical
Publication of CN110520416B publication Critical patent/CN110520416B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及一种多取代吡啶酮类衍生物、其制备方法及其医药用途。特别地，涉及通式(I)所示的多取代吡啶酮类衍生物、其制备方法、含有该衍生物的药物组合物，以及其作为Axl/c‑MET抑制剂用于治疗癌症的用途。其中通式(I)中的各基团的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201880024273.6A 2017-10-26 2018-10-12 多取代吡啶酮类衍生物、其制备方法及其医药用途 Active CN110520416B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711011780 2017-10-26
CN201711011780X 2017-10-26
PCT/CN2018/109969 WO2019080723A1 (zh) 2017-10-26 2018-10-12 多取代吡啶酮类衍生物、其制备方法及其医药用途

Publications (2)

Publication Number Publication Date
CN110520416A true CN110520416A (zh) 2019-11-29
CN110520416B CN110520416B (zh) 2022-06-03

Family

ID=66246754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880024273.6A Active CN110520416B (zh) 2017-10-26 2018-10-12 多取代吡啶酮类衍生物、其制备方法及其医药用途

Country Status (2)

Country Link
CN (1) CN110520416B (zh)
WO (1) WO2019080723A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527332A (zh) * 2020-04-13 2021-10-22 南开大学 具有生物活性的卡波特韦衍生物及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
CN112625027B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 杂环衍生物及其用途
CN111233779B (zh) * 2020-04-02 2021-08-20 廖文英 一种来氟米特的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005843A (zh) * 2004-06-28 2007-07-25 布里斯托尔-迈尔斯·斯奎布公司 吡咯并三嗪激酶抑制剂
CN101128199A (zh) * 2004-04-23 2008-02-20 布里斯托尔-迈尔斯斯奎布公司 作为激酶抑制剂的单环杂环
WO2011095045A1 (zh) * 2010-02-03 2011-08-11 上海源力生物技术有限公司 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用
WO2012006960A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
WO2012059041A1 (en) * 2010-11-02 2012-05-10 Centaurus Biopharma Co., Ltd. Novel 6-arylamino pyridone carboxamide as mek inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128199A (zh) * 2004-04-23 2008-02-20 布里斯托尔-迈尔斯斯奎布公司 作为激酶抑制剂的单环杂环
CN101005843A (zh) * 2004-06-28 2007-07-25 布里斯托尔-迈尔斯·斯奎布公司 吡咯并三嗪激酶抑制剂
WO2011095045A1 (zh) * 2010-02-03 2011-08-11 上海源力生物技术有限公司 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用
WO2012006960A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
WO2012059041A1 (en) * 2010-11-02 2012-05-10 Centaurus Biopharma Co., Ltd. Novel 6-arylamino pyridone carboxamide as mek inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527332A (zh) * 2020-04-13 2021-10-22 南开大学 具有生物活性的卡波特韦衍生物及其制备方法和应用

Also Published As

Publication number Publication date
CN110520416B (zh) 2022-06-03
WO2019080723A1 (zh) 2019-05-02

Similar Documents

Publication Publication Date Title
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
CN112368283B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
CN113423703A (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN116601148A (zh) 杂环类衍生物抑制剂、其制备方法和应用
CN110520416B (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
CN111484480A (zh) 一种多环类衍生物抑制剂、其制备方法和应用
CN109422755A (zh) 一种含氮杂环化合物、制备方法、中间体、组合物和应用
CN113195471B (zh) 多取代吡啶酮类衍生物及其在医药上的应用
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
CA2946459A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN114163454A (zh) 含吡啶多环类衍生物抑制剂、其制备方法和应用
TWI601724B (zh) 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
CN115956080A (zh) 双环化合物，包含其的组合物及其应用
CN111566100A (zh) 嘧啶类化合物、其制备方法及其医药用途
CN112292378A (zh) 含吲哚类衍生物抑制剂、其制备方法和应用
CN115724827A (zh) 稠环类衍生物抑制剂、其制备方法和应用
WO2020125513A1 (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN114644627A (zh) AhR抑制剂及其用途
CN113348170B (zh) 联苯类衍生物抑制剂、其制备方法和应用
TW202017928A (zh) 新穎三環化合物
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN117440945A (zh) 嘧啶或吡啶衍生物及其制备方法和在药学上的应用
CN109535132B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN115698005A (zh) 稠环类AhR抑制剂
CN115836064A (zh) 具有egfr抑制活性的三嗪衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221020

Address after: 215124 Floor 19, Building 1, Tianyun Plaza, No. 111, Wusongjiang Avenue, Guoxiang Street, Wuzhong District, Suzhou, Jiangsu

Patentee after: Suzhou Puhe Pharmaceutical Technology Co.,Ltd.

Address before: 102200 3rd floor, building 1, 29 shengshengyuan Road, Huilongguan town, Changping District, Beijing

Patentee before: BEIJING YUEZHIKANGTAI BIOMEDICINES Co.,Ltd.